Tomonori Ishii

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst et al. · The Lancet Respiratory Medicine · 2020 · 612 citations · Full text

Autoimmune Disease, Systemic Scleroderma, Immunology +3

Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)

Yoshikazu Nakaoka, Mitsuaki Isobe, Syuji Takei et al. · Annals of the Rheumatic Diseases · 2017 · 369 citations · Full text

Human parvovirus B19 as a causative agent for rheumatoid arthritis

Yuichi Takahashi, Chihiro Murai, S Shibata et al. · Proceedings of the National Academy of Sciences · 1998 · 274 citations

Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection

Yasuhiko Munakata, Takako Saito‐Ito, Keiko Kumura-Ishii et al. · Blood · 2005 · 177 citations · Full text

CD26-mediated signaling for T cell activation occurs in lipid rafts through its association with CD45RO

Tomonori Ishii, Kei Ohnuma, Akikazu Murakami et al. · Proceedings of the National Academy of Sciences · 2001 · 172 citations · Full text